ESTRO 2025 - Abstract Book

S2270

Interdisciplinary – Health economics & health services research

ESTRO 2025

Results: Among the 106.391 trials recorded since 2000, 87.748 trials were related to oncology. Only 402 (0.5%) and 7955 (9%) of them included brachytherapy or EBRT, respectively. While 25% of non-RT related trials had industrial funding, this proportion fell to 6.5% and 5.5% in brachytherapy and EBRT trials (p<0.001; Figure 1).

Ongoing trials related to brachytherapy, to EBRT and to other oncological topics were mostly multicentric (69.8% vs 64.4% vs 60%, p<0.001). Interventional trials are mostly randomized (77% vs 75.9% vs 66.4%, p<0.001) and early phase trials (defined as phase I and/or II; 70.5% vs 79% vs 82.9%, p<0.001). The international repartition of ongoing clinical trial sites was highly inequitable when considering trials related to brachytherapy or EBRT (Figure 2).